drugset / Trial / NCT06181227
A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema
RandomizedParallel-groupDouble-blindTreatment
Summary
A Phase 2 study to determine the safety and preliminary efficacy of intravitreal injections of AVD-104, a novel glyco-mimetic nanoparticle, in reducing macular edema associated with diabetic retinopathy.
Timeline
- Start
- 2023-11-30
- Primary completion
- 2024-04-05
- Completion
- 2024-04-05
Outcome
Outcome not reported
Stopped (Business): “The trial was stopped early due to insufficient study drug supply and study funding constraints”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AVD-104 | Other / unclassified | 1 mg | Intravitreal |
| Subject | AVD-104 | Other / unclassified | 2 mg | Intravitreal |